These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23222536)

  • 21. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Levey AS; Stevens LA
    N Engl J Med; 2011 Jan; 364(3):287; author reply 287-9. PubMed ID: 21247327
    [No Abstract]   [Full Text] [Related]  

  • 22. V2 receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment.
    Bennett WM
    J Am Soc Nephrol; 2005 Apr; 16(4):838-9. PubMed ID: 15728776
    [No Abstract]   [Full Text] [Related]  

  • 23. mTOR inhibitors in polycystic kidney disease.
    Watnick T; Germino GG
    N Engl J Med; 2010 Aug; 363(9):879-81. PubMed ID: 20581393
    [No Abstract]   [Full Text] [Related]  

  • 24. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
    N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polycystic kidney disease: a 2011 update.
    Steinman TI
    Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):189-94. PubMed ID: 22274800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    He Q; Lin C; Ji S; Chen J
    Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic interventions for autosomal dominant polycystic kidney disease.
    Edelstein CL
    Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
    Ponticelli C; Locatelli F
    Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121
    [No Abstract]   [Full Text] [Related]  

  • 29. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].
    Cornec-Le Gall E; Le Meur Y
    Nephrol Ther; 2014 Nov; 10(6):433-40. PubMed ID: 25086476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.
    Serra AL; Kistler AD; Poster D; Krauer F; Senn O; Raina S; Pavik I; Rentsch K; Regeniter A; Weishaupt D; Wüthrich RP
    Nephrol Dial Transplant; 2009 Nov; 24(11):3334-42. PubMed ID: 19525519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
    Wüthrich RP; Serra AL; Kistler AD
    Kidney Blood Press Res; 2009; 32(5):380-7. PubMed ID: 19887826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
    de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
    Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
    Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
    J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Better understanding of ADPKD results in potential new treatment options: ready for the cure?
    Meijer E; de Jong PE; Peters DJ; Gansevoort RT
    J Nephrol; 2008; 21(2):133-8. PubMed ID: 18446706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N; Cortinovis M; Remuzzi G
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.
    Soliman A; Zamil S; Lotfy A; Ismail E
    Transplant Proc; 2012 Dec; 44(10):2936-9. PubMed ID: 23195001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Volumetric analysis of MRI data monitoring the treatment of polycystic kidney disease in a mouse model.
    Hadjidemetriou S; Reichardt W; Hennig J; Buechert M; von Elverfeldt D
    MAGMA; 2011 Apr; 24(2):109-19. PubMed ID: 21213015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New options in the treatment of autosomal dominant polycystic kidney disease.
    Kazancioglu R; Gursu M
    Ren Fail; 2015 May; 37(4):535-41. PubMed ID: 25682970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR Inhibition and Kidney Diseases.
    Ma MKM; Yung S; Chan TM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal angiomyolipoma bleeding in a patient with TSC2/PKD1 contiguous gene syndrome after 17 years of renal replacement therapy.
    Furlano M; Barreiro Y; Martí T; Facundo C; Ruiz-García C; DaSilva I; Ayasreh N; Cabrera-López C; Ballarín J; Ars E; Torra R
    Nefrologia; 2017; 37(1):87-92. PubMed ID: 27595512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.